Mapp Biopharmaceutical Inc

Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals with an emphasis on monoclonal antibody therapeutics. The company has a strong track record of identifying potent monoclonals and advancing them through preclinical activities with non-dilutive financing. Mappbio’s portfolio consists of products for the prevention and treatment of a range of diseases including C. difficile, Ebola virus, and Respiratory Syncytial Virus (RSV) infections.